The regenerative medicine industry has a communication problem, and it isn’t a scientific one. The field now broadly accepts that mesenchymal stem/stromal cells (MSCs) exert their effects largely through paracrine signaling rather than engraftment and differentiation, a reframing captured in Arnold Caplan’s proposal to rename them “medicinal signaling cells.” What hasn’t matured is the public’s understanding of any of it. [Read more…]
How to Find a Stem Cell Clinical Trial for Your Condition
Are you or a loved on suffering from arthritis, multiple sclerosis (MS), COPD, Alzheimer’s disease, asthma, or other chronic condition? If so, how do you find a stem cell clinical trial?
This article provides the answers, including links to find a clinical trials near you, as well as links to clinical trials for specific conditions.Â
Cartherics and Catalent Expand Partnership, Securing Clinical-Grade iPSC Line for Next-Generation CAR-NK Therapies
MELBOURNE, Australia & TAMPA, FL – Cartherics Pty Ltd, a biotech company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, has announced an enhanced partnership.
The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced pluripotent stem cells (iPSC) line for the manufacture and commercialization of Cartherics’ iPSC-derived Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies. The agreement supports Cartherics’ mission to develop immune cell therapy products for the treatment of cancer and endometriosis. [Read more…]
Longevity Medical Institute® Publishes Systematic Review of Stem Cell Safety Based on Landmark Human Clinical Trials
LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 17, 2026 — Physicians and scientists from Longevity Medical Institute® have published new peer-reviewed research examining the safety of allogeneic mesenchymal stem cell therapies across a broad range of human clinical indications.
The study, titled “Safety of Allogeneic Mesenchymal Stromal Cell Therapy Across Human Clinical Indications: A Systematic Review of Landmark Clinical Trials and Published Safety Evidence,” reviewed more than 15 years of published human clinical research across more than 60 stem cell studies, approximately 4,000 patients, and multiple disease categories, including cardiovascular, pulmonary, autoimmune, gastrointestinal, renal, and orthopedic conditions. [Read more…]
Longevity Medical Institute® Physicians and Scientists Publish Peer-Reviewed Research on Stem Cell Therapies for Diabetic Foot Ulcers
LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 11, 2026 — Physicians and scientists from Longevity Medical Institute® have published new peer-reviewed research examining the therapeutic potential of allogeneic mesenchymal stem cell therapies for diabetic foot ulcers, one of the most serious and difficult-to-treat complications of diabetes. The publication adds to the growing body of evidence supporting stem cell-based approaches in chronic wound care and reflects Longevity Medical Institute’s broader investment in clinical research, diagnostics, and regenerative medicine infrastructure. [Read more…]
- 1
- 2
- 3
- …
- 24
- Next Page »